UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdi ...

Exhibit 99.1 Anaphylm is an oral epinephrine product candidate being developed for the treatment of type I allergic reactions, including anaphylaxis. The Company believes Anaphylm has the potential to be the first and only non-invasive, orally delivered epinephrine product for the treatment of type I allergic reactions, including anaphylaxis, if approved by the U.S. Food and Drug Administration (FDA). On September 16, 2026, the Company resubmitted its New Drug Application (NDA) for Anaphylm to the U.S. Food ...

Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approvedCommercial preparations remain on track to support a potential U.S. launch of Anaphylm following FDA approvalEx-U.S. Anaphylm strategy progressing, with Health Canada submission expected in Q4 2026 and an EU filing planned for Q1 2027Company to host investor call on November 4, 2026, at 8:00 a.m. ET ...

文章核心观点 - 四只制药与生物科技股票当日出现异常期权活动，涉及Inovio Pharmaceuticals、Aquestive Therapeutics、X4 Pharmaceuticals和Jazz Pharmaceuticals，期权成交量均显著放大 [1] - 尽管股价走势整体偏正面，但期权情绪出现分化，并非一致看多或看空 [1] Inovio Pharmaceuticals (INO) - 股价上涨5.3%至1.99美元，延续前一日涨势，此前美国食品药品监督管理局（FDA）授予VOCERYQ加速批准，用于减少成人复发性呼吸道乳头状瘤病（RRP）患者的手术频率 [2] - 期权成交量达到通常日内水平的5.8倍，共成交20,708份合约 [2] - 交易者情绪偏空，净期权delta成交量为负，约负62,000股 [2] Aquestive Therapeutics (AQST) - 股价上涨3.4%至3.90美元，但过去一个月累计下跌14.3% [3] - 期权成交量为5,080份，是日均日内水平的两倍 [3] - 情绪偏空，净期权delta成交量为负3,000股 [3] X4 Pharmaceuticals (XFOR) - 股价持平于3.34美元，已从10月中旬低点回升 [3] - 期权成交量达到通常日内水平的2.9倍，共成交3,838份合约 [3] - 交易者持看多立场，净期权delta成交量为正，约正40,000股 [3] Jazz Pharmaceuticals (JAZZ) - 股价领涨该组，上涨8.6%至232.94美元，此前公司公布创纪录的第三季度营收，受Ziihera和Modeyso两款治疗药物推动 [4] - 期权成交量达到通常日内水平的6.6倍，共成交2,108份合约 [4] - 情绪偏多，净期权delta成交量为正，约正11,000股 [4]